免疫系统
结直肠癌
肠道菌群
微生物群
癌症
炎症
免疫学
生物
免疫疗法
医学
生物信息学
内科学
作者
Forough Masheghati,Mohammad Reza Asgharzadeh,Abbas Jafari,Naser Masoudi,Hadi Maleki
出处
期刊:Life Sciences
[Elsevier]
日期:2024-05-01
卷期号:344: 122529-122529
被引量:3
标识
DOI:10.1016/j.lfs.2024.122529
摘要
The gut microbiome plays a significant role in developing colorectal cancer (CRC). The gut microbiome usually acts as a protective barrier against harmful pathogens and infections in the intestine, while also regulating inflammation by affecting the human immune system. The gut microbiota and probiotics play a role not only in intestinal inflammation associated with tumor formation but also in regulating anti-cancer immune response. As a result, they associated with tumor progression and the effectiveness of anti-cancer therapies. Research indicates that gut microbiota and probiotics can be used as biomarkers to predict the impact of immunotherapy and enhance its efficacy in treating CRC by regulating it. This review examines the importance of gut microbiota and probiotics in the development and progression of CRC, as well as their synergistic impact on anti-cancer treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI